Adverum Biotechnologies, Inc. Insider Trading for August 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Adverum Biotechnologies, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Adverum Biotechnologies, Inc. for August 2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Venrock Healthcare Capital Par ... | 10% Owner | Option Exercise | C | 0.00 | 1,965,471 | 0 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Venrock Healthcare Capital Par ... | 10% Owner | Buy | P | 17.00 | 400,000 | 6,800,000 | 2,365,471 | 2 M to 2.4 M (+20.35 %) |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Venrock Healthcare Capital Par ... | 10% Owner | Buy | C | 0.00 | 1,965,471 | 0 | 1,965,471 | 0 to 2 M |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Venrock Associates VI, L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,965,471 | 0 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Venrock Associates VI, L.P. | 10% Owner | Buy | P | 17.00 | 400,000 | 6,800,000 | 2,365,471 | 2 M to 2.4 M (+20.35 %) |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Venrock Associates VI, L.P. | 10% Owner | Buy | C | 0.00 | 1,965,471 | 0 | 1,965,471 | 0 to 2 M |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Zygtech, LLC | 10% Owner | Option Exercise | C | 0.00 | 295,115 | 0 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Zygtech, LLC | 10% Owner | Option Exercise | C | 0.00 | 2,799,269 | 0 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Zygtech, LLC | 10% Owner | Buy | C | 0.00 | 295,115 | 0 | 3,094,384 | 2.8 M to 3.1 M (+10.54 %) |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Zygtech, LLC | 10% Owner | Buy | C | 0.00 | 2,799,269 | 0 | 2,799,269 | 0 to 2.8 M |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Wachter Paul | Director | Option Exercise | C | 0.00 | 63,081 | 0 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Wachter Paul | Director | Buy | C | 0.00 | 63,081 | 0 | 63,081 | 0 to 63.1 K |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Schwartz Steven Daniel | Director | Option Exercise | C | 0.00 | 25,306 | 0 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Schwartz Steven Daniel | Director | Option Exercise | X | 0.00 | 6,620 | 0 | 25,306 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Schwartz Steven Daniel | Director | Option Exercise | X | 1.45 | 6,620 | 9,599 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Schwartz Steven Daniel | Director | Option Exercise | X | 0.15 | 34,000 | 5,100 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Schwartz Steven Daniel | Director | Buy | C | 0.00 | 25,306 | 0 | 559,306 | 534 K to 559.3 K (+4.74 %) |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Schwartz Steven Daniel | Director | Buy | X | 0.15 | 34,000 | 5,100 | 534,000 | 500 K to 534 K (+6.80 %) |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | MCLAUGHLIN JOHN PETER | Director | Option Exercise | C | 0.00 | 13,280 | 0 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | MCLAUGHLIN JOHN PETER | Director | Option Exercise | C | 0.00 | 13,280 | 0 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | MCLAUGHLIN JOHN PETER | Director | Buy | C | 0.00 | 13,280 | 0 | 13,280 | 0 to 13.3 K |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | MCLAUGHLIN JOHN PETER | Director | Buy | C | 0.00 | 13,280 | 0 | 13,280 | 0 to 13.3 K |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Hull Hans | SVP, Legal and Corp ... | Option Exercise | C | 0.00 | 3,320 | 0 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Hull Hans | SVP, Legal and Corp ... | Buy | C | 0.00 | 3,320 | 0 | 3,320 | 0 to 3.3 K |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Chalberg Thomas W. | Chief Executive Off ... | Option Exercise | C | 0.00 | 10,988 | 0 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Chalberg Thomas W. | Chief Executive Off ... | Option Exercise | X | 0.00 | 3,102 | 0 | 10,988 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Chalberg Thomas W. | Chief Executive Off ... | Option Exercise | X | 1.45 | 3,102 | 4,498 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Chalberg Thomas W. | Chief Executive Off ... | Buy | C | 0.00 | 10,988 | 0 | 370,988 | 360 K to 371 K (+3.05 %) |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Option Exercise | C | 0.00 | 12,531 | 0 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Option Exercise | X | 0.00 | 4,137 | 0 | 12,531 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Option Exercise | X | 1.45 | 4,137 | 5,999 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Option Exercise | C | 0.00 | 12,531 | 0 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Option Exercise | X | 0.00 | 4,137 | 0 | 12,531 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Option Exercise | X | 1.45 | 4,137 | 5,999 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Option Exercise | C | 0.00 | 12,531 | 0 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Option Exercise | X | 0.00 | 4,137 | 0 | 12,531 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Option Exercise | X | 1.45 | 4,137 | 5,999 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Option Exercise | C | 0.00 | 20,989 | 0 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Option Exercise | X | 0.00 | 5,689 | 0 | 20,989 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Option Exercise | X | 1.45 | 5,689 | 8,249 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Option Exercise | X | 0.15 | 25,000 | 3,750 | 0 | |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Buy | C | 0.00 | 12,531 | 0 | 12,531 | 0 to 12.5 K |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Buy | C | 0.00 | 12,531 | 0 | 12,531 | 0 to 12.5 K |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Buy | C | 0.00 | 12,531 | 0 | 12,531 | 0 to 12.5 K |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Buy | C | 0.00 | 20,989 | 0 | 745,989 | 725 K to 746 K (+2.90 %) |
| Aug 07 2014 | AAVL | Adverum Biotechnol ... | Blumenkranz Mark S. | Director | Buy | X | 0.15 | 25,000 | 3,750 | 725,000 | 700 K to 725 K (+3.57 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | REGENERON PHARMACEUTICALS INC | 10% Owner | Option Exercise | C | 0.00 | 531,208 | 0 | 0 | |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | REGENERON PHARMACEUTICALS INC | 10% Owner | Option Exercise | C | 0.00 | 689,655 | 0 | 0 | |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | REGENERON PHARMACEUTICALS INC | 10% Owner | Buy | P | 17.00 | 588,235 | 9,999,995 | 1,809,098 | 1.2 M to 1.8 M (+48.18 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | REGENERON PHARMACEUTICALS INC | 10% Owner | Buy | C | 0.00 | 531,208 | 0 | 1,220,863 | 689.7 K to 1.2 M (+77.03 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | REGENERON PHARMACEUTICALS INC | 10% Owner | Buy | C | 0.00 | 689,655 | 0 | 689,655 | 0 to 689.7 K |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 531,208 | 0 | 0 | |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 147,410 | 0 | 0 | |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 184,594 | 0 | 0 | |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 24.57 | 31,650 | 777,641 | 627,267 | 595.6 K to 627.3 K (+5.31 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.35 | 49,981 | 1,316,999 | 595,617 | 545.6 K to 595.6 K (+9.16 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.14 | 27,600 | 721,464 | 545,636 | 518 K to 545.6 K (+5.33 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 27.54 | 12,400 | 341,496 | 518,036 | 505.6 K to 518 K (+2.45 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.42 | 219,864 | 5,808,807 | 505,636 | 285.8 K to 505.6 K (+76.94 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.79 | 18,700 | 482,273 | 285,772 | 267.1 K to 285.8 K (+7.00 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.52 | 9,800 | 250,096 | 267,072 | 257.3 K to 267.1 K (+3.81 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.41 | 201,972 | 5,132,109 | 257,272 | 55.3 K to 257.3 K (+365.23 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 55,300 | 940,100 | 55,300 | 0 to 55.3 K |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 24.57 | 25,600 | 628,992 | 507,200 | 481.6 K to 507.2 K (+5.32 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.35 | 40,400 | 1,064,540 | 481,600 | 441.2 K to 481.6 K (+9.16 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.14 | 22,400 | 585,536 | 441,200 | 418.8 K to 441.2 K (+5.35 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 27.54 | 10,100 | 278,154 | 418,800 | 408.7 K to 418.8 K (+2.47 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.42 | 177,700 | 4,694,834 | 408,700 | 231 K to 408.7 K (+76.93 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.79 | 15,100 | 389,429 | 231,000 | 215.9 K to 231 K (+6.99 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.52 | 7,900 | 201,608 | 215,900 | 208 K to 215.9 K (+3.80 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.41 | 163,300 | 4,149,453 | 208,000 | 44.7 K to 208 K (+365.32 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 44,700 | 759,900 | 44,700 | 0 to 44.7 K |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 123,077 | 2,092,309 | 654,285 | 531.2 K to 654.3 K (+23.17 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 34,223 | 581,791 | 181,633 | 147.4 K to 181.6 K (+23.22 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 42,700 | 725,900 | 227,294 | 184.6 K to 227.3 K (+23.13 %) |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 531,208 | 0 | 531,208 | 0 to 531.2 K |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 147,410 | 0 | 147,410 | 0 to 147.4 K |
| Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 184,594 | 0 | 184,594 | 0 to 184.6 K |
| Aug 01 2014 | AAVL | Adverum Biotechnol ... | Chalberg Thomas W. | Chief Executive Off ... | Option Exercise | A | 17.00 | 80,000 | 1,360,000 | 80,000 | |
| Aug 01 2014 | AAVL | Adverum Biotechnol ... | Wachter Paul | Director | Option Exercise | A | 17.00 | 75,000 | 1,275,000 | 75,000 | |
| Aug 01 2014 | AAVL | Adverum Biotechnol ... | Gasmi Mehdi | VP, Pharmaceutical ... | Option Exercise | A | 17.00 | 70,000 | 1,190,000 | 70,000 | |
| Aug 01 2014 | AAVL | Adverum Biotechnol ... | MCLAUGHLIN JOHN PETER | Director | Option Exercise | A | 17.00 | 75,000 | 1,275,000 | 75,000 | |
| Aug 01 2014 | AAVL | Adverum Biotechnol ... | Hull Hans | SVP, Legal and Corp ... | Option Exercise | A | 17.00 | 75,000 | 1,275,000 | 75,000 |